<!----> Ortho Clinical Diagnostics Trading has signed a definitive agreement to form a joint venture (JV) with Shanghai...

<!----> PAVmed’s digital health subsidiary Veris Health has announced the commercial roll out of its Veris Cancer Care...

<!----> Molecular diagnostic solutions provider BioGX has launched its portable pixl qPCR real-time PCR platform Ex-US with an...

<!----> Halo Diagnostics has announced a partnership with Ikonopedia, a breast imaging reporting and tracking solution, to offer...

Chinese cancer early detection solutions developer AnchorDx has enrolled the first participant in the clinical trial of its...

Image by Editor  The community known as Kaggle is the go-to platform for machine learning data science buffs who want to collaborate with like-minded...

The assay covers mutations of HER2, BRAF, PIK3CA, EGFR and KRAS; translocations of ALK and ROS1; and MET exon 14 skipping.

The post Genetron, Hutchmed partner to develop diagnostic for Orpathys in China appeared first on Medical Device Network.

Company adds experienced clinical development expert to its board of directors OSLO, Norway–(BUSINESS WIRE)–Oncoinvent AS announces that Adrian Senderowicz was elected as a Non-executive Director today at the Company’s Extraordinary General Meeting. Adrian Senderowicz is a US Board certified medical oncologist, and President of Oncology Drug Development, LLC. Adrian is a highly experienced and talented […]

The post Oncoinvent appoints Adrian Senderowicz MD to its Board of Directors appeared first on Fintech News.

Mark Fernandez, principal investigator for Spaceborne Computer-2, sees a promising future for space-based computing.

The post Hewlett Packard Enterprise’s space station computer is in demand appeared first on SpaceNews.

The Signatera test is designed to monitor treatment and analyse molecular residual disease (MRD) in patients with cancer.

The post Natera’s MRD test predicts benefit of chemotherapy for colorectal cancer appeared first on Medical Device Network.

Chimeric antigen receptor (CAR) T cells have revolutionized cancer treatment. CARs use antibody-derived binding domains to redirect T cells to antigens expressed on the surface of cancer cells. However, the high affinity of most currently used CAR-binding domains results in excessive T-cell activation limiting CAR T-cell persistence and the inability to differentiate between antigen-high tumor cells and antigen-low healthy cells. We review recent data on the use of low-affinity CAR-binding domains and evaluate technologies and approaches to engineer and screen low-affinity antibody variants for CAR T-cell development.

Almost 40% of people will receive a cancer diagnosis at some point during their lives, according to the National Cancer Institute. This statistic makes it obvious why governments, universities, and...

The post Here’s How Cancer Treatments are Evolving appeared first on IP.com - IP Innovation and Analytics.